Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder that is caused by the abnormality in the ABCD1 gene present on the X chromosome, leading to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland.
Adrenoleukodystrophy Epidemiological Segmentation
The Epidemiological Segmentation of Adrenoleukodystrophy in 7MM from 2017 to 2030 is segmented as:-
- Total Prevalent Population of Adrenoleukodystrophy
- Gender-specific Prevalence of Adrenoleukodystrophy
- Gender-specific Diagnosed Prevalent Population of Adrenoleukodystrophy
- Type-specific Diagnosed Prevalence in males of Adrenoleukodystrophy
- The total prevalent population of Adrenoleukodystrophy in the 7MM in 2017 was 55,242
- The prevalent population of Adrenoleukodystrophy in the United States in 2017 was 19,371
- Among the EU5, Germany had the highest diagnosed prevalent population of Adrenoleukodystrophy was 1,699
Adrenoleukodystrophy Market Size in the United States in 2017 was USD 523.26 million
Adrenoleukodystrophy Market Drivers
- Increased number of potential therapies in the pipeline
- Awareness about newborn screening programs
- The rise in the number of Childhood Cerebral Adrenoleukodystrophy (CALD) cases
Adrenoleukodystrophy Emerging Drugs
Adrenoleukodystrophy Emerging Drugs are Lenti D, Leriglitazone, MD1003, MGTA-456, OP-101, SOM1201, and many others.
Adrenoleukodystrophy Key Players
Adrenoleukodystrophy key players are bluebird bio, Minoryx Therapeutics, S.L., MedDay Pharmaceuticals, Magenta Therapeutics, Orpheris Inc, SOM Biotech, and many others.